The new draft guidelines favor earlier DMARD therapy with ‘much decreased reliance on glucocorticoids that have several side ...

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

Please provide your email address to receive an email when new articles are posted on . Among patients with rheumatoid arthritis, observed rates of major adverse events from biologic/targeted ...

Patients with psoriatic arthritis who received bDMARDs vs cDMARDs had a lower risk for major adverse cardiovascular events, all-cause mortality, and cardiovascular mortality. Biologic ...

Worries have persisted that cancer survivors in remission might face increased recurrence risk when treated with biologic drugs for autoimmune disease. This Danish study of rheumatoid arthritis ...

ROME — Daily baricitinib, an oral Janus kinase (JAK)1/2 inhibitor, produces rapid clinical improvement in the signs and symptoms of rheumatoid arthritis in patients with active disease who have failed ...